Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Often, investors and Wall Street analysts focus on the short term and don't give enough thought to the long term.

The absence of insider selling at Pfizer (PFE) after a sizable one-year rally is a data point retail investors should be weighing. The signal reflects the steady hand of professionals who see the ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Pfizer Inc PFE shares are dipping on Tuesday. The company announced a series of settlement agreements that extend the effective U.S. patent life of Vyndamax, its treatment for transthyretin‑mediated ...

Pfizer's declining revenue and questions about its growth have weighed down the stock in recent years. The company, however, has been bolstering its pipeline and has some exciting assets. Its ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

US stock market surges today: why Dow Jones, S&P 500, and Nasdaq are rallying sharply despite global tensions? The Dow Jones Industrial Average jumps over 350 points. The S&P 500 pushes to fresh highs ...

Screen the most attractively valued U.S. large-cap stocks ($10B+) using Seeking Alpha’s valuation grades—top cheap picks include PFE, FNMA, FMCC & more.

Stocks soared to new highs in earlier day trading after Pfizer said Monday that its latest data show that the drugmaker's coronavirus vaccine is highly effective. Investors also breathed a sigh of ...